Cargando…

A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma

Clear cell Renal Cell Carcinoma (ccRCC) is one of the most prevalent kidney cancers, which is often asymptomatic and thus discovered at a metastatic state (mRCC). mRCC are highly heterogeneous tumors composed of subclonal populations that lead to poor treatment response rate. Several recent works ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Séraudie, Irinka, Pillet, Catherine, Cesana, Beatrice, Bazelle, Pauline, Jeanneret, Florian, Evrard, Bertrand, Chalmel, Frédéric, Bouzit, Assilah, Battail, Christophe, Long, Jean-Alexandre, Descotes, Jean Luc, Cochet, Claude, Filhol, Odile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517165/
https://www.ncbi.nlm.nih.gov/pubmed/37736770
http://dx.doi.org/10.1038/s41419-023-06133-z
_version_ 1785109269882863616
author Séraudie, Irinka
Pillet, Catherine
Cesana, Beatrice
Bazelle, Pauline
Jeanneret, Florian
Evrard, Bertrand
Chalmel, Frédéric
Bouzit, Assilah
Battail, Christophe
Long, Jean-Alexandre
Descotes, Jean Luc
Cochet, Claude
Filhol, Odile
author_facet Séraudie, Irinka
Pillet, Catherine
Cesana, Beatrice
Bazelle, Pauline
Jeanneret, Florian
Evrard, Bertrand
Chalmel, Frédéric
Bouzit, Assilah
Battail, Christophe
Long, Jean-Alexandre
Descotes, Jean Luc
Cochet, Claude
Filhol, Odile
author_sort Séraudie, Irinka
collection PubMed
description Clear cell Renal Cell Carcinoma (ccRCC) is one of the most prevalent kidney cancers, which is often asymptomatic and thus discovered at a metastatic state (mRCC). mRCC are highly heterogeneous tumors composed of subclonal populations that lead to poor treatment response rate. Several recent works explored the potential of ccRCC tumoroids culture derived from patients. However, these models were produced following a scaffold-based method using collagen I or Matrigel that exhibit lot variability and whose complexity could induce treatment response modifications and phenotypic alterations. Following the observation that ccRCC tumoroids can create their own niche by secreting extracellular matrix components, we developed the first scaffold-free tumoroid model of ccRCC tumors. Tumoroids from mice as well as from human tumors were generated with high success rate (≥90%) using a magnetic suspension method and standard culture media. Immunofluorescence analysis revealed their self-organization capacities to maintain multiple tumor-resident cell types, including endothelial progenitor cells. Transcriptomic analysis showed the reproducibility of the method highlighting that the majority of gene expression patterns was conserved in tumoroids compared to their matching tumor tissue. Moreover, this model enables to evaluate drug effects and invasiveness of renal cancer cells in a 3D context, providing a robust preclinical tool for drug screening and biomarker assessment in line with alternative ex vivo methods like tumor tissue slice culture or in vivo xenograft models.
format Online
Article
Text
id pubmed-10517165
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105171652023-09-24 A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma Séraudie, Irinka Pillet, Catherine Cesana, Beatrice Bazelle, Pauline Jeanneret, Florian Evrard, Bertrand Chalmel, Frédéric Bouzit, Assilah Battail, Christophe Long, Jean-Alexandre Descotes, Jean Luc Cochet, Claude Filhol, Odile Cell Death Dis Article Clear cell Renal Cell Carcinoma (ccRCC) is one of the most prevalent kidney cancers, which is often asymptomatic and thus discovered at a metastatic state (mRCC). mRCC are highly heterogeneous tumors composed of subclonal populations that lead to poor treatment response rate. Several recent works explored the potential of ccRCC tumoroids culture derived from patients. However, these models were produced following a scaffold-based method using collagen I or Matrigel that exhibit lot variability and whose complexity could induce treatment response modifications and phenotypic alterations. Following the observation that ccRCC tumoroids can create their own niche by secreting extracellular matrix components, we developed the first scaffold-free tumoroid model of ccRCC tumors. Tumoroids from mice as well as from human tumors were generated with high success rate (≥90%) using a magnetic suspension method and standard culture media. Immunofluorescence analysis revealed their self-organization capacities to maintain multiple tumor-resident cell types, including endothelial progenitor cells. Transcriptomic analysis showed the reproducibility of the method highlighting that the majority of gene expression patterns was conserved in tumoroids compared to their matching tumor tissue. Moreover, this model enables to evaluate drug effects and invasiveness of renal cancer cells in a 3D context, providing a robust preclinical tool for drug screening and biomarker assessment in line with alternative ex vivo methods like tumor tissue slice culture or in vivo xenograft models. Nature Publishing Group UK 2023-09-22 /pmc/articles/PMC10517165/ /pubmed/37736770 http://dx.doi.org/10.1038/s41419-023-06133-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Séraudie, Irinka
Pillet, Catherine
Cesana, Beatrice
Bazelle, Pauline
Jeanneret, Florian
Evrard, Bertrand
Chalmel, Frédéric
Bouzit, Assilah
Battail, Christophe
Long, Jean-Alexandre
Descotes, Jean Luc
Cochet, Claude
Filhol, Odile
A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma
title A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma
title_full A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma
title_fullStr A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma
title_full_unstemmed A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma
title_short A new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in Renal Cell Carcinoma
title_sort new scaffold-free tumoroid model provides a robust preclinical tool to investigate invasion and drug response in renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517165/
https://www.ncbi.nlm.nih.gov/pubmed/37736770
http://dx.doi.org/10.1038/s41419-023-06133-z
work_keys_str_mv AT seraudieirinka anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT pilletcatherine anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT cesanabeatrice anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT bazellepauline anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT jeanneretflorian anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT evrardbertrand anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT chalmelfrederic anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT bouzitassilah anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT battailchristophe anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT longjeanalexandre anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT descotesjeanluc anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT cochetclaude anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT filholodile anewscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT seraudieirinka newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT pilletcatherine newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT cesanabeatrice newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT bazellepauline newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT jeanneretflorian newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT evrardbertrand newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT chalmelfrederic newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT bouzitassilah newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT battailchristophe newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT longjeanalexandre newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT descotesjeanluc newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT cochetclaude newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma
AT filholodile newscaffoldfreetumoroidmodelprovidesarobustpreclinicaltooltoinvestigateinvasionanddrugresponseinrenalcellcarcinoma